Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kent Gleed

Clinical Cardiac Electrophysiology Hays, KS Medical Doctor

NPI 1669449997 CMS profile 211042

2220 Canterbury Dr, Hays, KS 67601

Open in the dashboard

General payments

$15,194

316 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,184 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Kent Gleed of Hays, KS is reported in the CMS Open Payments database as having received $15,194 across 316 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,184 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 44th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,171 36
2023 General $2,228 54
2022 General $1,959 56
2021 General $2,578 60
2020 General $1,662 36
2019 General $4,597 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kent Gleed
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Kent Gleed were reported at $0. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Kent Gleed Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,597 $2,361 $585–$8,260 $163
2020 $1,662 $993 $247–$4,351 $114
2021 $2,578 $1,185 $326–$4,739 $132
2022 $1,959 $2,073 $554–$6,789 $149
2023 $2,228 $2,568 $759–$8,159 $160
2024 $2,171 $2,557 $703–$7,403 $164
2025 $0 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic, Inc. $5,591 56 payments
  2. Medtronic Vascular, Inc. $3,979 38 payments
  3. Abbott Laboratories $2,273 43 payments
  4. Boston Scientific Corporation $1,155 63 payments
  5. Impulse Dynamics (USA) Inc. $493 13 payments
  6. Novartis Pharmaceuticals Corporation $245 17 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $243 16 payments
  8. Biosense Webster, Inc. $216 5 payments
  9. Merck Sharp & Dohme Corporation $160 10 payments
  10. Pfizer Inc. $142 10 payments
  11. Other $697 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,004 292 payments
  2. Travel and Lodging $7,120 23 payments
  3. Education $70 1 payment
Products named General payments · program years 2019–2024
  1. Arctic Front $2,546 14 payments
  2. Micra $2,196 25 payments
  3. EVERA MRI XT DR SURESCAN $1,238 6 payments
  4. SelectSecure $1,040 10 payments
  5. Cardiovascular- Research only $1,013 4 payments
  6. OPTIMIZER Cardiovascular Device $470 12 payments
  7. OPTIMIZER Cardiovascular Device $470 12 payments
  8. WATCHMAN Access System $317 15 payments
  9. EnSite Precision Cardiac Mapping System $286 10 payments
  10. ENSITE PRECISION $260 10 payments
  11. Other $4,649 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

295

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$97,395

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

59%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 109 $77,358
Xarelto Rivaroxaban Brand 18 $15,323
Flecainide Acetate Generic 41 $2,671
Metoprolol Succinate Generic 55 $1,129
Amiodarone Hcl Generic 25 $326
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $250
Sotalol Sotalol Hcl Brand 22 $222
Clopidogrel Clopidogrel Bisulfate Brand 13 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$104,490

Medicare's payments for the services billed

Medicare patients

437

Average age 75

Services billed

1,638

214 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 73%
Heart failure 52%
Arthritis 50%
Ischemic heart disease 45%
Chronic kidney disease 35%
Diabetes 33%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $61
$61 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $31
  • PFIZER INC. $16
$47 109 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $23
$23 — —
Repatha
  • Amgen Inc. $17
$17 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record